Mindfront Health Opens New Outpatient Center in Shanghai to Provide World-Class Mental Hea...

Luye Pharma’s Innovative Long-acting Microspheres Injection LY03009 Soon to Begin Clinica...

for treating Parkinson's disease (PD) and restless legs syndrome (RLS).

Marketing Authorization Application for Luye Pharma's Denosumab Injection Accepted in Chin...

Clinical trials of the drug in Europe and the U.S. are making good progress

Boan Biotech’s New ADCC-Enhanced Anti-Claudin 18.2 Antibody Drug BA1105 Approved for Clin...

For treating Claudin18.2-positive advanced solid tumors.

Luye Pharma’s Class 1 New Drug LY03015 Soon to Begin Clinical Trials in China The drug is...

LY03015 is used for the treatment of Tardive Dyskinesia and Huntington's Disease.

Research Results of Luye Pharma’s Next-Generation VMAT2 Inhibitor LY03015 Published in Eu...

The results demonstrate LY03015’s high binding affinity for VMAT2 and excellent inhibition of DA uptake, indi...